Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE

Prospective rAndomized, Single-blind, multicenTral Control Clinical Trial of Sirolimus-eluting coRonary Stent "Calypso" (Angioline) vs Everolimus-elutIng cOronary stenT "Xience Prime" (Abbott Vascular)

The aim of the study is to evaluate the efficacy and safety of sirolimus-eluting coronary stent "Calypso" (Angioline, Russia) in comparison with everolimus-eluting coronary stent "Xience" (Abbott Vascular, USA)

Inclusion Criteria:

• Patients considered for coronary angioplasty with stenting due to Ischemic heart disease (Stable angina, Unstable angina, non-ST Myocardial Infarction).
• Target vessel lesion in coronary artery with diameter measurements >2.5 mm & < 4.5 mm.
• Signed, documented informed consent prior to admission to the study

Exclusion Criteria:

• Age <18 years or >75 years
• Renal insufficiency (GFR/MDRD <30 ml/min)
• Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.
• Known non-adherence to DAPT
• LVEF <30%
• Known oncology
• Severe cardiac valvular pathology, requiring operative treatment within 1 year
• Anemia (HB<100 g/l)
• Continuing bleeding
• Acute coronary syndrome (ST-elevation Myocardial infarction)
• Anamnesis of previous coronary angioplasty/stenting or CABG
• NYHA class (dyspnoea) IV or hospitalization during last year due to Chronic cardiac failure as a primary diagnosis.
• Pregnancy
• Coronary pathology requiring CABG or staged scheduled coronary angioplasty/stenting except cases of unscheduled staged coronary angioplasty/stenting within 4 weeks after primary procedure.